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introDuCtion
Multiple myeloma (MM) is a malignant plasma cell disease 
which predominately affects the axial skeleton and prox-
imal long bones.1 The National Institute for Health and 
Care Excellence (NICE) in England currently recommends 
that imaging is offered to all patients suspected of myeloma, 
and to consider whole body MRI as first-line imaging for 
detection of myeloma bone involvement.2 Whole body MRI 
has also been recommended in patients with myeloma with 
serological relapse or disease progression2 and at the Royal 
Marsden Hospital is also used for assessing response in 
high risk groups. Recent consensus from the International 
Myeloma Working Group is also influencing increased used 
of whole body MRI.3 Whole body diffusion-weighted MRI 
has become a core component of whole body MRI proto-
cols in oncology due to its high sensitivity, relative speed 
and quantitative capabilities.4
Patients on treatment for multiple myeloma are at risk of 
avascular necrosis (AVN). Current first-line antineoplastic 
and first relapse treatment recommendations include the 
addition of corticosteroids, usually dexamethasone, along-
side high-dose chemotherapeutic agents.2 Corticosteroids 
have been shown to reduce blood flow to the affected bone, 
and AVN is thought to be sequelae of impeded blood supply 
causing death of osteocytes.5 Further risk factors include 
diabetes, cumulative dexamethasone dose, radiotherapy, 
alcoholism, infections, coagulopathies and autoimmune 
conditions.6
Early detection of AVN may allow for treatment regimen 
modification, including lowering of the cumulative dose of 
corticosteroids to minimise risk of femoral head collapse 
and regular monitoring of those at higher risk.5 Early stage 
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objective: Current therapies for multiple myeloma, 
which include corticosteroids, increase risk of avascular 
necrosis. The aim of this study was to assess incidental 
detection of femoral head avascular necrosis on routine 
whole body MRI including diffusion weighted MRI.
methods: All whole body MRI studies, performed on 
patients with known multiple myeloma between 1 
January 2010 to 1 May 2017 were assessed for features 
of avascular necrosis.
results: 650 whole body MR scans were analysed. 15 
patients (6.6%) had typical MR features of avascular 
necrosis: 2/15 (13.3%) had femoral head collapse, 4/15 
(26.7%) had bilateral avascular necrosis and 9/15 (60%) 
were asymptomatic.
Conclusion: This is the first report of avascular necrosis 
detected on routine whole body MRI in patients with 
multiple myeloma. Targeted review of femoral heads 
in multiple myeloma patients undergoing whole body 
MR is recommended, including in patients without 
symptoms.
advances in knowledge: Whole body MR which 
includes diffusion-weighted MRI is extremely sensi-
tive for evaluation of bone marrow. Although 
whole body MRI is primarily used for evaluation of 
multiple myeloma disease burden, it also presents 
an unique opportunity to evaluate the femoral heads 
for signs of avascular necrosis which can predate 
symptoms.
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with disease progression. MRI is the most sensitive diagnostic 
imaging test for AVN with a reported sensitivity of 90–100% and 
specificity of 100%.7,8
The aim of this study was to assess the incidence of AVN detec-
tion on routine whole-body MRI including diffusion-weighted 
MR, in patients with multiple myeloma.
methoDS anD materialS
Local institutional review board approval was obtained. We 
performed a retrospective analysis of all whole body MRI studies 
performd on patients with an established diagnosis of MM 
between 1 January 2010 and 1 May 2017 at the Royal Marsden 
Hospital. Patients with incomplete scan protocols were excluded.
Scan protocol
Using an Avanto and Aera 1.5 T system (Siemens, Erlangen, 
Germany) a WB study was achieved by the serial acquisition of 
contiguous body regions. All subjects were scanned supine with 
arms by their sides. Coil elements were positioned from skull 
vertex to knees. Sagittal T1 weighted images [repetition time 
(TR) 590 ms, echo time (TE) 11 ms, field of view (FOV) 400 mm, 
slice thickness 4 mm], and T2 weighted images (TR 2690 ms, TE 
93 ms, FOV 400 mm, slice thickness 4 mm) of the spine were 
acquired, followed by axial diffusion-weighted sequences (single-
shot double spin echo echoplanar technique with short tau inver-
sion-recovery fat suppression in free breathing) using b-values 
of 50 and 900 s/mm2 applied in three orthogonal directions and 
combined to the isotropic trace images. Diffusion-weighted 
images were acquired in multiple contiguous stations of 50 slices 
per station (slice thickness 5 mm, no gap, FOV 430 mm, phase 
direction anteroposterior, parallel imaging (GRAPPA) factor 2, 
TR 14800 ms, TE 66 ms, inversion time (TI) 180 ms, voxel size 
2.9 x 2.9 x 5 mm, number of signal averages 4, matrix 150 × 150, 
bandwidth 1960 Hz per pixel). Axial T1 weighted Vibe Dixon 
three-dimensional gradient echo breath-hold sequences (52 
slices per slab, FOV 470 mm, TR/TE 7/2.38, 4.76 ms, flip angle 
30, matrix 192 × 192) were also acquired, matching the acquisi-
tion stacks and partition thickness to the DWI.
Data collection
All scans were initially reported by a consultant radiologist 
with a specialist interest in MM for whom review for features 
of AVN is standard practice. All whole body MRI studies were 
retrospectively independently reviewed to assess for the presence 
of features of AVN and signs of progressing AVN. Features of 
femoral head AVN were defined as: low serpiginous signal band 
on axial T1 weighted Vibe Dixon and femoral head fragmenta-
tion/collapse assessed on all sequences. Oedema was also evalu-
ated on b50 DW MRI and ADC maps. Clinical history including 
dexamethasone, radiotherapy and bisphosphonate use and 
disease activity as per International Myeloma Working Group 
criteria3 were recorded from the Electronic Patient Records.
reSultS
Between 1 January 2010 and 1 May 2017, 650 whole body MR 
scans were performed in 226 patients with an established diagnosis 
of MM. 15 of these patients (6.6%) (10 male, 5 female, median age 
66.5 years (range 31–74) were identified to have typical MR features 
of AVN.4/15 (27%) had a known history of AVN. Indications for 
scan included disease assessment post-treatment (6/15), biochem-
ical progression (5/15) or reported bone pains at other sites (1/15). 
In addition to subchondral serpiginous lines, and oedema which 
were evident on all sequences (Figure 1), in each of the 15 patients, 
2/15 had femoral head collapse and 4/15 had bilateral AVN. 10/15 
patients had active disease according to IMWG criteria and 8/15 
were being treated with steroid-combination regimens. Median 
cumulative dexamethasone dose received by these patients was 
540 mg (range 80–5040 mg) while 3/15 had received prior pelvic 
radiotherapy. None of these patients had a background of diabetes. 
All patients were receiving bisphosphonates on a monthly to 
bi-monthly basis. 6/15 patients reported symptoms in the affected 
hip(s) at the time of AVN detection. 10/15 were referred for ortho-
paedic review.
The majority of these patients continued to have follow-up 
scans (9/15) for disease assessment, with a mean duration of 7.2 
months (range 2–12).
During surveillance, 8/9 patients showed features of worsening 
AVN on follow-up MRI scans, including worsening femoral 
head oedema and increasing effusions. Of these, 4/8 reported 
worsening symptoms in the affected hip(s) and subsequently 
required surgical intervention with total hip replacements. All 
other patients were managed conservatively and are continuing 
to be reviewed by the orthopaedic team.
DiSCuSSion
AVN is a known complication of steroid therapy and there-
fore patients with MM are at risk. Symptoms often occur at late 
stage femoral head collapse at which time non-surgical treatment 
options are limited. In keeping with previous published data, 
which has shown a 9% incidence of AVN in patients5 with MM, the 
incidence of AVN in our MM patients imaged with routine whole 
body MRI was low (6.6%). However, we have demonstrated that 
asymptomatic AVN can be detected before femoral head collapse 
which provides a window of opportunity for minimally invasive 
management. Although abnormal signal on diffusion-weighted 
MRI in the femoral heads has been reported in children with AVN 
this is the first report of diffusion-weighted MRI for detection of 
AVN in adults and the first report of asymptomatic femoral head 
AVN detection on whole body MRI in patients with MM.9 The 
retrospective nature of this data collection, limited number of 
cases and lack of standardised follow-up poses limitations and we 
propose prospective studies to further establish the natural history 
and risk factors for MM patients developing AVN. Studies on the 
relative contributions of the different imaging sequences are also 
desirable.
AVN can have a substantial effect on a patient’s morbidity and 
quality of life as AVN progresses to femoral head collapse and osteo-
arthritis.10 Femoral head AVN is a rapidly progressing pathology 
reportedly with a 70–80% chance of femoral head collapse after 3 
years.10 A further study examining hips in 50 patients with early 
MRI features of AVN, over a period of 49 months, reported 32% of 
the femoral heads had collapsed by 32 months.11
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Whole body MR is useful for early detection of AVN in those 
that are asymptomatic and for monitoring progression. Despite 
having radiological features of AVN, 60% were asymptom-
atic and of those patients followed up 89% demonstrated more 
advanced imaging features of AVN.
MRI is the most propitious imaging modality in the investiga-
tion of early femoral osteonecrosis and asymptomatic contralat-
eral disease. A combination of clinical and radiological findings 
guide orthopaedic surgeons in managing femoral head osteone-
crosis. Early detection allows for prompt referral and consider-
ation of non-surgical options.
Imaging drives management decision-making in femoral osteo-
necrosis. There are a number of imaging-based classification 
systems used to stratify femoral head osteonecrosis, e.g. the Ficat 
and Arlet classification.12 Measurement of the size of any cortical 
defect present, at the mid-sagittal and mid-coronal MR planes 
may be useful for decision-making and have been implicated 
in predicting future femoral head collapse.13 However, accurate 
measurements may require dedicated small FOV images but the 
need for such measurements will be guided by preference of the 
local orthopaedic surgeons.
Pharmacological therapy such as Alendronate (a bisphospho-
nate) which is routinely part of the myeloma regimen has been 
shown to prevent early femoral head collapse.14 However, despite 
all of our patients with MRI features of AVN were being treated 
with bisphosphonate agents.
Surgical options for early stage AVN are not yet standard prac-
tice. These aim to preserve the femoral head, include core 
decompression, either with or without bone grafting which 
involves drilling of small holes through the subchondral necrosis 
to stimulate a healing response through angiogenesis and reduce 
intraosseous pressure.15 The success of novel therapies such as 
bone tissue engineering which may offer reparative potential 
avoiding complications of surgery, will be reliant on early detec-
tion.16 For advanced femoral head osteonecrosis, with resulting 
subchondral collapse, treatment options are usually restricted to 
more extensive surgery such as total hip replacements and total 
hip resurfacing.
It is interesting to note that although the frequency of incidental 
findings is high in patients with myeloma undergoing whole body 
MRI (70 in 175 examinations).17 Wale et al reported that only 
3% of whole body MRI scans in patients with myeloma resulted 
in the need for further investigation. Most incidental findings 
were not significant, however, as AVN can be a significant cause 
of morbidity for patients with myeloma routine review of the 
femoral heads on whole body MRI is recommended.
ConCluSion
Whole body MR will be increasingly used for the evaluation of 
patients with MM. Patients with MM are often on high dose 
steroid regimens and are at increased risk of femoral head osteo-
necrosis. Femoral head AVN can progress quickly and may have 
devastating consequences for the patient’s quality of life neces-
sitating surgical intervention which may be challenging in the 
presence of co-morbidities.
This is the first study demonstrating that AVN can be detected 
on routine whole body MRI, including diffusion-weighted MRI 
in patients with MM. Evaluation of femoral heads in all multiple 
Figure 1. Axial MRI images (A: b50 diffusion-weighted MRI, 
B: corresponding apparent diffusion coefficient map, C: T1W 
MRI) of a 52-year-old lady on thalidomide and dexamethasone 
maintenance therapy. Bilateral subchondral signal changes 
(arrows) are evident on the diffusion weighted MRI (A, B) and 
on T1W MRI (C). No femoral symptoms were reported at the 
Mme of imaging which was performed for back pain. LeP hip 
replacement was performed 2 years following on from this 
scan due to pain.
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myeloma patients undergoing whole body MR should therefore 
be an integral part of the radiologist’s review.
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